GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK70) » Definitions » 3-Year Dividend Growth Rate

Conduit Pharmaceuticals (FRA:ZK70) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals 3-Year Dividend Growth Rate?

Conduit Pharmaceuticals's Dividends per Share for the three months ended in Sep. 2024 was €0.00.

The historical rank and industry rank for Conduit Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:

FRA:ZK70's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 9.6
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Conduit Pharmaceuticals's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Conduit Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Conduit Pharmaceuticals's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Conduit Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conduit Pharmaceuticals's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's 3-Year Dividend Growth Rate falls into.


;
;

Conduit Pharmaceuticals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Conduit Pharmaceuticals  (FRA:ZK70) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Conduit Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Sep. 2024 )/ EPS without NRI (Q: Sep. 2024 )
=0/ -5.961
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Conduit Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>


Conduit Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4995 Murphy Canyon Road, Suite 300, San Diego, CA, USA, 92123
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines